ABVX.PA Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 18:35):

Stats
Dzisiejszy wolumen	13 478.00
Średni wolumen	30 185.00
Kapitalizacja rynkowa	932.44M
EPS	€0 ( 2024-04-07 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-4.32
ATR14	€0.0470 (0.32%)

Wolumen Korelacja

Długi: -0.05 (neutral)

Krótki: 0.77 (moderate)

Signal:(59.774) Neutral

Abivax SA Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Abivax SA Korelacja - Waluta/Towar

0.39
( neutral )

0.49
( neutral )

0.00
( neutral )

0.58
( weak )

-0.55
( weak negative )

-0.73
( moderate negative )

Abivax SA Finanse

Annual	2023
Przychody:	€4.62M
Zysk brutto:	€3.91M (84.70 %)
EPS:	€-3.43

FY	2023
Przychody:	€4.62M
Zysk brutto:	€3.91M (84.70 %)
EPS:	€-3.43

FY	2022
Przychody:	€0
Zysk brutto:	€-71 000.00 (0.00 %)
EPS:	€-3.13

FY	2021
Przychody:	€37 000.00
Zysk brutto:	€37 000.00 (100.00 %)
EPS:	€-3.39

Financial Reports:

No articles found.

Abivax SA

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.